Whitehawk Therapeutics, Inc. (WHWK) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00032Q1040
Whitehawk Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 7.15 m USD |
| Gross profit | 6.39 m USD |
| Operating income | -114.40 m USD |
| EBIT | -26.83 m USD |
| Net income | -20.60 m USD |
| Diluted EPS – continuing operations | -0.33 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
More stocks
- Delta Plus Group SA (ALDLT.PA)
- QUICKLOGIC Corp (QUIK)
- AUDIOEYE INC (AEYE)
- Advanced Process Systems Corporation (265520.KQ)
- Foresight Financial (FGFH)
- Cho Kwang Leat (004700.KS)
- Tera Autotech (6234.TWO)
- Euro Cervantes SOCIMI SA (YEUR.MC)
- Mkango Resources Ltd (MKA.V)
- Kwong Lung Enterprise Co Ltd (8916.TWO)
- Hansun Engineering Co., Ltd. (452280.KQ)
- Intelligent Hotel Group Ltd. (ZHJD)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.